Calle Silvia de la, Zurita Mercedes
Cell Therapy Unit, Puerta de Hierro Hospital, Majadahonda, Madrid, 28222 Spain.
Cell Therapy Unit Responsable, Puerta de Hierro Hospital, Majadahonda, Madrid, 28222 Spain.
Regen Ther. 2025 Jun 12;30:173-181. doi: 10.1016/j.reth.2025.05.011. eCollection 2025 Dec.
Hemorrhagic stroke, which is also called an intracerebral hemorrhage, is a cerebrovascular disease that represents a serious public health problem worldwide. Among all types of stroke, intracerebral hemorrhage causes the highest percentage of mortality and morbidity, affecting 2 million people annually, with no specific treatment established except for rehabilitation-oriented techniques. In recent years, new alternatives have been sought to treat this type of pathology, with mesenchymal stem cell therapy gaining special relevance. These cells present a series of biological properties, including regenerative repair, neuroprotection, and immunomodulation that make them a tool with enormous potential in regenerative medicine. In this review, we are going to focus on clinical trials and clinical studies which use cell therapy with Mesenchymal Stem Cells as a treatment for patients suffering from intracerebral hemorrhage. The clinical trials found are not very numerous. It remains an area to be explored; however, existing studies suggest it is a safe therapy that yields positive neurological and functional outcomes in many treated patients. All of this makes it a very promising and encouraging therapy for patients with this type of pathology.
出血性中风，也称为脑出血，是一种脑血管疾病，在全球范围内都是严重的公共卫生问题。在所有类型的中风中，脑出血导致的死亡率和发病率最高，每年影响200万人，除了以康复为主的技术外，尚无特定的治疗方法。近年来，人们一直在寻找治疗这种疾病的新方法，间充质干细胞疗法受到了特别关注。这些细胞具有一系列生物学特性，包括再生修复、神经保护和免疫调节，使其成为再生医学中具有巨大潜力的工具。在这篇综述中，我们将重点关注使用间充质干细胞进行细胞治疗脑出血患者的临床试验和临床研究。发现的临床试验数量并不多。这仍是一个有待探索的领域；然而，现有研究表明，这是一种安全的疗法，在许多接受治疗的患者中产生了积极的神经和功能结果。所有这些都使其成为治疗此类疾病患者非常有前景和令人鼓舞的疗法。
